Additionally, GLP-1 receptor agonists have shown cardiovascular benefits and are recommended for reducing the risk of major cardiovascular events in patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk [63]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.